Therapeutic Apheresis in Immunologic Renal and Neurological Diseases

被引:12
作者
Bambauer, Rolf [1 ]
Latza, Reinhard [2 ]
Burgard, Daniel [3 ]
Schiel, Ralf [4 ]
机构
[1] Inst Blood Purificat, Homburg, Germany
[2] Laboratorium Med, St Ingbert, Germany
[3] Heart Ctr Duisburg, Duisburg, Germany
[4] Inselklin Heringsdorf GmbH, Heringsdorf, Germany
关键词
Immunoadsorption; Immunologic diseases; Neurologic diseases; Renal; Therapeutic apheresis; Therapeutic plasma exchange; GUILLAIN-BARRE-SYNDROME; DONOR KIDNEY-TRANSPLANTATION; INTRAVENOUS IMMUNE GLOBULIN; ANCA-ASSOCIATED VASCULITIS; POSITIVE CROSS-MATCH; PLASMA-EXCHANGE; ALLOGRAFT-REJECTION; NERVOUS-SYSTEM; IMMUNOADSORPTION; PLASMAPHERESIS;
D O I
10.1111/1744-9987.12499
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Since the mid 1970s, when membrane modules became available, plasma separation techniques have gained in importance especially in the past few years. The advantages of this method are a complete separation of the corpuscular components from the plasma and due to increased blood flow rate and higher efficacy. Systemic autoimmune diseases based on an immune pathogenesis produce autoantibodies and circulating immune complexes, which cause inflammation in the tissues of various organs. In most cases, these diseases have a poor prognosis without treatment. Therapeutic apheresis (TA) in combination with immunosuppressive therapies has led to a steady increase in survival rates over the last 40years. The updated information on immunology and molecular biology of different immunologic diseases are discussed in relation to the rationale for apheresis therapy and its place in combination with other modern treatments. The different diseases can be treated by various apheresis methods such as therapeutic plasma exchange (TPE) with substitution solution, or with online plasma or blood purification using adsorption columns, which contain biological or non-biological agents. Here, the authors provide an overview of the most important pathogenic aspects indicating that TA can be a supportive therapy in systemic autoimmune diseases such as renal and neurological disorders. For the immunological diseases that can be treated with TA, the guidelines of the German Working Group of Clinical Nephrology and of the Apheresis Committee of the American Society for Apheresis are cited.
引用
收藏
页码:6 / 21
页数:16
相关论文
共 95 条
[1]   Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathy [J].
Allen, D ;
Giannopoulos, K ;
Gray, I ;
Gregson, N ;
Makowska, A ;
Pritchard, J ;
Hughes, RAC .
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2005, 10 (02) :174-180
[2]   Antiglycolipid antibodies in Guillain-Barre syndrome and related diseases: Review of clinical features and antibody specificities [J].
Ariga, T ;
Yu, RK .
JOURNAL OF NEUROSCIENCE RESEARCH, 2005, 80 (01) :1-17
[3]   Thymectomy is more effective than conservative treatment for myasthenia gravis regarding outcome and clinical improvement [J].
Bachmann, Kai ;
Burkhardt, Doreen ;
Schreiter, Inken ;
Kaifi, Jussuf ;
Schurr, Paulus ;
Busch, Christoph ;
Thayssen, Gunther ;
Izbicki, Jakob R. ;
Strate, Tim .
SURGERY, 2009, 145 (04) :392-398
[4]  
Bagga A, 2005, INDIAN J MED RES, V122, P13
[5]   THERAPEUTIC PLASMA-EXCHANGE IN HEMOLYTIC-UREMIC SYNDROME [J].
BAMBAUER, R ;
JUTZLER, GA ;
JESBERGER, HJ ;
GRAF, N ;
LIMBACH, HG ;
SITZMANN, FC ;
KEUTH, U .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1988, 113 (31-32) :1245-1249
[6]  
Bambauer R, 2012, ARPN J SCI TECHNOL, V2, P399
[7]  
Bambauer R, 2013, THERAPEUTIC PLASMA E
[8]  
Bambauer R, 2014, CLIN NEPHROL UROL SC, DOI [10.7243/2054-7161-1-2, DOI 10.7243/2054-7161-1-2]
[9]   Therapeutic Apheresis in Immunologic Renal and Neurological Diseases [J].
Bambauer, Rolf ;
Latza, Reinhard ;
Burgard, Daniel ;
Schiel, Ralf .
THERAPEUTIC APHERESIS AND DIALYSIS, 2017, 21 (01) :6-21
[10]   Therapeutic Apheresis in the Treatment of Hemolytic Uremic Syndrome in View of Pathophysiological Aspects [J].
Bambauer, Rolf ;
Latza, Reinhard ;
Schiel, Ralf .
THERAPEUTIC APHERESIS AND DIALYSIS, 2011, 15 (01) :10-19